Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Research & Development (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Research & Development data on record, last reported at $50.8 million in Q4 2025.

  • For Q4 2025, Research & Development rose 23.94% year-over-year to $50.8 million; the TTM value through Dec 2025 reached $197.1 million, up 54.42%, while the annual FY2025 figure was $197.1 million, 54.42% up from the prior year.
  • Research & Development reached $50.8 million in Q4 2025 per OCUL's latest filing, down from $52.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $52.4 million in Q3 2025 and bottomed at $10.9 million in Q1 2021.
  • Average Research & Development over 5 years is $24.5 million, with a median of $15.1 million recorded in 2023.
  • Peak YoY movement for Research & Development: decreased 5.48% in 2022, then skyrocketed 153.1% in 2024.
  • A 5-year view of Research & Development shows it stood at $12.6 million in 2021, then rose by 7.67% to $13.5 million in 2022, then grew by 19.58% to $16.2 million in 2023, then surged by 153.1% to $41.0 million in 2024, then increased by 23.94% to $50.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $50.8 million in Q4 2025, $52.4 million in Q3 2025, and $51.1 million in Q2 2025.